Some studies confirmed Creld2 is the crucial gene and a viable therapeutic target for hepatic steatosis and hepatocellular carcinoma (Liu et al., 2019; Kern et al., 2021). This evidence concerns the gene CRELD2 and hepatocellular carcinoma.